To read the full story, subscribe or sign in.

Gemini Ascendant: Axsome questions, get good phase III answers in MDD

Dec. 16, 2019

Fueled by new positive data, Axsome Therapeutics Inc. plans to seek approval during the second half of 2020 for its dextromethorphan/bupropion modulated delivery tablet, AXS-05, an oral NMDA receptor antagonist to treat major depressive disorder.

BioWorld Clinical Neurology/Psychiatric

Data needed for Chinese COVID-19 vaccines against Delta variant

BioWorld Asia

The lack of data surrounding the efficacy of Chinese COVID-19 vaccines against the Delta variant has had many questioning them, especially after a recent study...

Data needed for Chinese COVID-19 vaccines against Delta variant

BioWorld

The lack of data surrounding the efficacy of Chinese COVID-19 vaccines against the Delta variant has had many questioning them, especially after a recent study...

Today's news in brief

BioWorld

BioWorld briefs for July 30.

Today's news in brief

BioWorld MedTech

BioWorld MedTech's briefs for July 30.

Aicuris heads for phase III with herpes drug pritelivir

BioWorld

Aicuris Anti-Infective Cures AG is beginning the pivotal phase III part of its trial of pritelivir for herpes simplex virus infection after an encouraging...